Results 51 to 60 of about 4,566 (189)

Identification of Mispairing Omic Signatures in Chinese Hamster Ovary (CHO) Cells Producing a Tri-Specific Antibody

open access: yesBiomedicines, 2023
Monoclonal antibody-based therapy has shown efficacy against cancer, autoimmune, infectious, and inflammatory diseases. Multispecific antibodies (MsAbs), including trispecifics (tsAbs), offer enhanced therapeutic potential by targeting different epitopes.
Maria João Sebastião   +7 more
doaj   +1 more source

Natural Products as Modulators of ABC Transporters in Breast Cancer

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT Breast cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in early detection and treatment. Multidrug resistance (MDR), particularly in aggressive subtypes like triple‐negative breast cancer (TNBC), continues to hinder effective therapy.
Yoganishalini Sagadevan   +2 more
wiley   +1 more source

Diagnostic antibodies at an inflection point: From discovery platforms to design‐oriented engineering

open access: yesVIEW, EarlyView.
This study systematically organizes the evolution of diagnostic antibodies from discovery platforms to design‐oriented engineering and analyzes the strengths and limitations of each approach. Meanwhile, it provides a critical, literature‐driven synthesis of current challenges, proposing integrated strategies for assay‐aware and function‐driven antibody
Qitao Song   +14 more
wiley   +1 more source

Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays [PDF]

open access: yes, 2019
Idiopathic inflammatory myopathies (IIM) are a group of diseases characterized by immune-mediated muscular lesions that may be associated with extra-muscular manifestations involving skin, lungs, heart or joints.
Chen, Yi-Hsing   +13 more
core   +3 more sources

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

open access: yesVIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin   +3 more
wiley   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

open access: yesVIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Structure-guided design of antibody CDRs to reduce their reactivity to treatment-emergent anti-drug antibodies

open access: yesmAbs
Immunogenicity prediction is widely used in the developability assessment of antibodies, and many marketed and clinical-stage therapeutics have a predicted T-cell epitope in the second complementary-determining region of their light chain (CDR2L).
Maria U. Johansson   +13 more
doaj   +1 more source

MODELLING, SIMULATION AND VISUALIZATION OF A MULTISPECIFIC PHILIPPINE SEAGRASS MEADOW [PDF]

open access: yesThe International Archives of the Photogrammetry, Remote Sensing and Spatial Information Sciences, 2019
Seagrass meadows are constantly under threat from natural and man-made stresses due to its shallow existence in the coastal environment. Restoration and preservation of seagrasses by means of rehabilitation or transplanting strategies is possible, but ...
V. P. Bongolan   +2 more
doaj   +1 more source

Engineered mRNA and the Rise of Next-Generation Antibodies

open access: yesAntibodies, 2021
Monoclonal antibodies are widely used as therapeutic agents in medicine. However, clinical-grade proteins require sophisticated technologies and are extremely expensive to produce, resulting in long lead times and high costs.
Laura Sanz, Luis Álvarez-Vallina
doaj   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

open access: yesBritish Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Home - About - Disclaimer - Privacy